| ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ |
PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ as follows: |
globenewswire.com |
2025-05-12 22:30:00 |
Czytaj oryginał (ang.) |
| ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why |
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
zacks.com |
2025-05-12 17:50:46 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript |
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants Gary Nachman - Raymond James Faisal Khurshid - Leerink Partners Vamil Divan - Guggenheim Securities David Amsellem - Piper Sandler Ekaterina Knyazkova - J.P. Morgan Les Sulewski - Truist Securities Operator Please stand by. |
seekingalpha.com |
2025-05-09 15:44:46 |
Czytaj oryginał (ang.) |
| Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? |
Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year. |
zacks.com |
2025-05-09 14:46:24 |
Czytaj oryginał (ang.) |
| Compared to Estimates, ANI (ANIP) Q1 Earnings: A Look at Key Metrics |
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-09 14:30:43 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates |
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.70 per share, beating the Zacks Consensus Estimate of $1.37 per share. This compares to earnings of $1.21 per share a year ago. |
zacks.com |
2025-05-09 13:10:41 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance |
BAUDETTE, Minn., May 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended March 31, 2025. |
globenewswire.com |
2025-05-09 10:50:00 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals: A Short-Term Buying Opportunity |
ANIP is expected to raise 2025 guidance due to FDA approval and launch of TEZRULY and INZIRQO, addressing unmet needs for dysphagic patients. Both drugs are patent protected until 2042 and offer new formulations of established drugs, minimizing launch expenses and maximizing market potential. INZIRQO and TEZRULY could generate significant revenue, with potential annual revenues of $1 billion and $350 million respectively, driving ANIP's PPS higher. |
seekingalpha.com |
2025-05-06 09:43:18 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards? |
ANIP's first-quarter 2025 revenues are likely to have been driven by increased sales of its lead product, Cortrophin Gel, and other rare disease products. |
zacks.com |
2025-05-05 17:15:33 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue? |
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2025-05-05 14:15:35 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model |
Demonstrated Dose Dependent Effect in EAU Presented in a podium presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2025 annual meeting PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced preclinical data on the use of Purified Cortrophin® Gel (repository corticotropin injection USP) (Cortrophin Gel) in an EAU mouse model. |
globenewswire.com |
2025-05-05 11:00:00 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release |
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-02 15:06:13 |
Czytaj oryginał (ang.) |
| 3 Reasons Growth Investors Will Love ANI (ANIP) |
ANI (ANIP) could produce exceptional returns because of its solid growth attributes. |
zacks.com |
2025-04-25 17:45:35 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? |
Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year. |
zacks.com |
2025-04-23 14:46:22 |
Czytaj oryginał (ang.) |
| Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue |
It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Stride, 908 Devices, & Contango are well-poised to gain. |
zacks.com |
2025-04-23 13:30:40 |
Czytaj oryginał (ang.) |
| 5 Stocks With Recent Price Strength Amid Tariff-Led Volatility |
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are HRTG, MRX, KINS, ANIP, HCI. |
zacks.com |
2025-04-23 11:05:33 |
Czytaj oryginał (ang.) |
| 4 Stocks Trading Near 52-Week High With Room to Rise Further |
Investors target stocks that have been on a bullish run lately. Stocks like ANIP, HRTG, AVA and EXC are seeing price strength and the momentum is likely to continue. |
zacks.com |
2025-04-22 13:25:41 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals, Inc. (ANIP) Soars to 52-Week High, Time to Cash Out? |
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2025-04-17 14:15:38 |
Czytaj oryginał (ang.) |
| 3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP) |
ANI (ANIP) could produce exceptional returns because of its solid growth attributes. |
zacks.com |
2025-04-09 17:45:37 |
Czytaj oryginał (ang.) |
| Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? |
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-04-09 17:15:53 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March |
PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and select members of senior management, will present at two upcoming investor conferences as follows: Raymond James & Associates' 46 th Annual Institutional Investors Conference Tuesday, March 4, 2025, at 1:40pm ET Leerink Partners Global Healthcare Conference Tuesday, March 11, 2025, at 3:40pm ET The live and archived webcasts will be accessible from the Company's website at www.anipharmaceuticals.com , under the Investors section under Events and Presentations. |
globenewswire.com |
2025-02-19 18:30:00 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET |
PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to the market open. |
globenewswire.com |
2025-02-18 18:05:00 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-02-17 12:46:15 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? |
Here is how ANI Pharmaceuticals (ANIP) and Doximity (DOCS) have performed compared to their sector so far this year. |
zacks.com |
2025-02-17 12:41:12 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals: More Than Just A Generics Company |
ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue growth, strategic moves, and overlooked royalty streams indicate long-term value creation. ANI's rare disease asset, Purified Cortrophin Gel, and generics pipeline, including Prucalopride, position it for significant revenue growth and market re-rating. |
seekingalpha.com |
2025-02-11 11:08:03 |
Czytaj oryginał (ang.) |
| Is ANI Pharmaceuticals (ANIP) Stock Undervalued Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-01-31 12:46:32 |
Czytaj oryginał (ang.) |
| Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? |
Here is how ANI Pharmaceuticals (ANIP) and CG Oncology, Inc. (CGON) have performed compared to their sector so far this year. |
zacks.com |
2025-01-31 12:40:29 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference |
PRINCETON, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the Guggenheim Biotech Conference in New York City as follows: |
globenewswire.com |
2025-01-28 18:30:00 |
Czytaj oryginał (ang.) |
| Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-01-15 12:46:29 |
Czytaj oryginał (ang.) |
| Alcami Announces CEO Transition |
Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries DURHAM, N.C. , Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the resignation of Bill Humphries. |
prnewswire.com |
2025-01-13 13:12:00 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook |
BAUDETTE, Minn., Jan. 13, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today affirmed its prior net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS guidance for 2024 and provided its preliminary financial outlook for 2025. Nikhil Lalwani, ANI's President and Chief Executive Officer, will discuss these updates as part of a presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15 PST/5:15 EST. |
globenewswire.com |
2025-01-13 08:50:00 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity |
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company has launched Prucalopride Tablets. ANI's Prucalopride Tablets is the generic version of the reference listed drug (RLD) Motegrity®. |
globenewswire.com |
2025-01-02 08:50:00 |
Czytaj oryginał (ang.) |
| Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? |
Here is how ANI Pharmaceuticals (ANIP) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year. |
zacks.com |
2025-01-01 12:51:42 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
PRINCETON, N.J., Dec. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer; Stephen Carey, Chief Financial Officer; and Dr. Mary Pao, Chief Medical Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15pm PST/5:15pm EST, in San Francisco. |
globenewswire.com |
2024-12-30 18:05:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About ANI (ANIP) Rating Upgrade to Buy |
ANI (ANIP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-12-26 15:01:21 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-12-18 12:46:32 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-12-02 17:26:48 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference |
PRINCETON, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024 at 3pm EST in NYC. |
globenewswire.com |
2024-11-26 18:30:00 |
Czytaj oryginał (ang.) |
| Does ANI (ANIP) Have the Potential to Rally 31.31% as Wall Street Analysts Expect? |
The consensus price target hints at a 31.3% upside potential for ANI (ANIP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-11-26 12:55:16 |
Czytaj oryginał (ang.) |
| ANI (ANIP) Upgraded to Buy: What Does It Mean for the Stock? |
ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-11-20 15:00:29 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-11-14 12:45:50 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call Transcript |
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q3 2024 Earnings Conference Call November 8, 2024 8:00 AM ET Company Participants Lisa Wilson - IR Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants David Amsellem - Piper Sandler Gary Nachman - Raymond James Vamil Divan - Guggenheim Securities Operator Good day, everyone, and welcome to today's ANI Pharmaceuticals Inc Third Quarter 2024 Earnings Results Call. Please note that this call is being recorded. |
seekingalpha.com |
2024-11-09 01:05:28 |
Czytaj oryginał (ang.) |
| Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics |
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-11-08 13:02:12 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates |
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.27 per share a year ago. |
zacks.com |
2024-11-08 11:05:16 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance |
BAUDETTE, Minn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the three months ended September 30, 2024. |
globenewswire.com |
2024-11-08 08:50:00 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November |
PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at at two upcoming investor conferences as follows: |
globenewswire.com |
2024-11-04 18:30:00 |
Czytaj oryginał (ang.) |
| Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline |
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-11-01 13:06:19 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET |
PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2024 financial results on Friday, November 8, 2024, prior to the market open. |
globenewswire.com |
2024-10-30 19:00:00 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06% |
PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Estradiol Gel, 0.06%. ANI's Estradiol Gel, 0.06% is the generic version of the reference listed drug (RLD) EstroGel® Gel, 0.06%. |
globenewswire.com |
2024-10-25 10:50:00 |
Czytaj oryginał (ang.) |
| ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024 |
Two poster presentations demonstrate ANI's commitment to research in membranous nephropathy care Two poster presentations demonstrate ANI's commitment to research in membranous nephropathy care |
globenewswire.com |
2024-10-24 10:50:00 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-10-21 14:46:11 |
Czytaj oryginał (ang.) |